Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers
A Comparison of Effects of Short-term Low Dose Exposure of Advagraf® and Neoral® Microemulsion Cyclosporine A on Renal Perfusion and Function in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3X 2H9
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- caucasian
- healthy with no history or current clinical findings of infection or disease of the following nature: cerebrovascular, neurologic, cardiovascular, endocrine, pulmonary, immunologic, metabolic, hematologic, diabetes mellitus, glucose intolerance, gout
- non-smoker and willing to abstain from alcohol consumption during the study
- agrees to use appropriate contraception during the study period until 3 months after the final study exam.
Exclusion Criteria:
- history of significant alcohol abuse or drug abuse within 1 year prior to the screening visit
- regular use of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol per week)
- use of soft drugs (marijuana) within 3 months prior to the screening visit or hard drugs (cocaine, PCP, crack) within 1 year prior to the screening visit Hepatitis B or C, HIV, history of cancer (excluding excised squamous or basal cell carcinoma)
- positive tuberculin skin test or prior TB infection
- known history of serious head injuries, seizures or any eating disorder
- received an investigational drug within 30 days prior to the first study drug administration
- known hypersensitivity/allergy to tacrolimus, cyclosporine, iothalamate iodine, para-aminohippuric acid, antibiotics or antifungals
- Body mass index (BMI) <19 or >27
- clinically significant history of psychiatric disease or a significant disability that prevents understanding or adherence to protocol
- renal dysfunction, serum creatinine or urine microalbumin above the normal age and gender-adjusted reference range of the local lab
- clinically significant abnormal liver function test indicative of impaired hepatic function
- received medications/herbal preparations that may affect the metabolism of tacrolimus or cyclosporine A within 1 month of the first study drug administration
- received any other prescription medication within 14 days prior to the first study drug administration or any over-the-counter product within 7 days prior to the first study drug administration, except for topical products without systemic absorption
- current GI condition known to affect GI motility and/or absorption
- donation of plasma (500 mL) within 7 days prior to the first study drug administration or donation/ loss of whole blood as follows: 50 mL to 499 mL within 30 days or more than 499 mL within 56 days prior to the first study drug administration
- clinically significant surgery within 4 weeks prior to the first study drug administration
- administration of steroids by injection within 12 weeks prior to the first study drug administration
- administration of any live vaccine within 7 days prior to the first study drug administration
- travel in areas where TB is endemic within 8 weeks prior to the TB skin test performed at the screening visit
- hemoglobin <140 g/L
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: A. tacrolimus first
Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
|
oral
Other Names:
oral
Other Names:
|
|
EXPERIMENTAL: B. cyclosporine first
Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
|
oral
Other Names:
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison of Effective Renal Plasma Flow response
Time Frame: Baseline and Day 10 of each dosing interval
|
Baseline and Day 10 of each dosing interval
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison of Glomerular Filtration Rate response
Time Frame: Baseline and Day 10 of each dosing interval
|
Baseline and Day 10 of each dosing interval
|
|
Comparison of blood pressure response
Time Frame: Baseline and Day 10 of each dosing interval
|
Baseline and Day 10 of each dosing interval
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FKC-012
- Health Canada Control # 119562
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.